Jean-Yves Le Drian, Minister for Europe and Foreign Affairs, and Agnès Buzyn, Minister for Solidarity and Health, will host, at the Quai d’Orsay on September 12, the presentation of the report on the 2018 results of the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria by Peter Sands, Executive Director of the Global Fund. Charles Gomis, Ambassador of Côte d’Ivoire to France, and Professor Hakima Himmich, Chair of the NGO Coalition plus, will also speak. The session will be moderated by Stéphanie Seydoux, Ambassador for Global Health.
The presentation will be preceded by a session on mobilizing the private sector, jointly organized with the (RED) organization founded by Bono and in partnership with the French Council of Investors in Africa and Salesforce France, aimed at encouraging French and international business leaders to invest in global health.
The event, which is being held under the high patronage of President Macron, will launch preparations for the Sixth Replenishment Conference of the Global Fund due to take place in Lyon on October 10, 2019, aimed at raising, for the 2020-2022 programming period, the private and public funding needed to continue its mission to combat major pandemics. AIDs, tuberculosis and malaria continue to represent a major threat to global health. The mobilization of sufficient financial resources is vital in order to avoid the re-emergence of these pandemics and the explosion of resistant forms of tuberculosis and malaria.
The decision to host this conference reaffirms France’s historic commitment to global health. France has been at the forefront of international mobilization since the early 2000s by helping to create the innovative mechanism of the Global Fund, to which it is historically the second largest donor, with €4.2 billion in contributions within the framework of its policy to implement the Sustainable Development Goals. The Global Fund now operates in more than 100 developing countries and represents 57% of global funding to combat malaria, 20% for HIV/AIDS and 65% for tuberculosis, allowing for exceptional progress in access to treatment and the prevention of epidemics.